ReviewJournal of gastroenterology2008
Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside.
Review in Journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer.Cell death & disease · 2023Article
- Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth.Cell death & disease · 2021Article
- Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.Yonsei medical journal · 2018Article
- EFNB2 acts as the target of miR-557 to facilitate cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma by bioinformatics analysis and verification.American journal of translational research · 2018Article
- Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells.Annals of gastroenterological surgery · 2018Article
- Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Nature reviews. Clinical oncology · 2016Review
- The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.DNA and cell biology · 2015Article
- Garlic Oil Suppressed Nitrosodiethylamine-Induced Hepatocarcinoma in Rats by Inhibiting PI3K-AKT-NF-κB Pathway.International journal of biological sciences · 2015Article
- Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers.World journal of gastroenterology · 2014Review
- Article
- Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.PloS one · 2013Article
- FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis.International journal of medical sciences · 2013Article
- Plasma Shh levels reduced in pancreatic cancer patients.Pancreas · 2012Article
- Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.Journal of gastroenterology · 2012Article
- Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.Journal of carcinogenesis · 2012Article
- Article
- dmGWAS: dense module searching for genome-wide association studies in protein-protein interaction networks.Bioinformatics (Oxford, England) · 2011Article
- Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer.Genes & cancer · 2010Article
- Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.Molecular cancer therapeutics · 2010Article
- Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells.BMC cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current medical interventions for pancreatic cancer are insufficient. Recent molecular investigations have elucidated complex genetic mechanisms of cancer that especially involve multiple signal transduction pathways; this enables us to develop molecular medicines targeting specific genetic molecules in the pathways. These molecular medicines seem to promise clues for curing cancers, including pancreatic cancer. This review describes current knowledge and perspectives regarding the development of molecular medicines for pancreatic cancer by focusing on growth factor receptor systems and three major signal transduction pathways: the RAS-MAPK, PI3K-AKT-mTOR, and hedgehog pathways.
Indexed as
Identifiers
19107333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.